Osteopontin expression and prognostic significance in non-small cell lung cancer

Clinical Cancer Research

Volumn 11, Issue 18, 2005, Pages 6459-6465

  Donati, Valentins ^a   Boldrini, Laura ^a   Dell'Omodarme, Matteo ^b   Prati, Maria C ^b   Faviana, Pinuccia ^a   Camacci, Tiziano ^a   Lucchi, Marco ^a   Mussi, Alfredo ^a   Santoro, Massimo ^c   Basolo, Fulvio ^a   Fontanini, Gabriella ^a  

^a UNIVERSITY OF PISA   (Italy)

^b SCUOLA NORMALE SUPERIORE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OSTEOPONTIN; PROGNOSIS; SIALOGLYCOPROTEINS; SURVIVAL ANALYSIS;

EID: 25144491548     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0541     Document Type: Article

References (31)

1. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7.
2. Naruke T, Goya T, Tsuchiy AR, et al. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988;96:440-7.
3. Sorensen ES, Hojruo P, Petersen TE. Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci 1995;4:2040-9.
4. Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol 1993;13:225-46.
5. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000;11:279-303.
6. Reinholt FP, Hultenby K, Oldberg A, et al. Osteopontin: a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA 1990;87:4473-5.
7. Giachelli CM, Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 2000;19:615-22.
8. Shijubo N, Uede T, Kon S, et al. Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncol 2000;11:135-46.
9. Denhardt DT, Noda M, O'Regan AW, et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodelling, and cell survival. J Clin Invest 2001;107:1055-61.
10. Weber GF, Ashkar S, Glimcher MJ, et al. Receptor-ligand interaction between CD44 and osteopontin (n-1). Science 1996;271:509-12.
11. 1-containing integrins; to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motilityand chemotaxis. Cancer Res 1999;59:216-26.
12. Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 1997;121:578-84.
13. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 2001;6:419-29.
14. Chambers AF, Wilson SM, Kerkvliet N, et al. Osteopontin expression in lung cancers. Lung Cancer 1996;15:311-23.
15. Thalmann GN, Sikes RA, Devoll RE, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 1999;5:2271-7.
16. Agrawal D, ChenT, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002;94:513-21.
17. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Dir Assoc 2002;287:1671-9.
18. Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998;79:127-32.
19. FurgerKA, Menon RK, Tuck AB, et al. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001;1:621-32.
20. Oates AJ, Barraclough R, Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 1997;17:1-15.
21. Weber GF, Ashkar S. Stress response genes-the genes that make cancer metastasize. J Mol Med 2000;78:404-8.
22. Arch R, Wirth K, Hofmann M, et al. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 1992;257:682-5.
23. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 2001;1552:61-85.
24. Zhang J, Takahashi K, Takahashi F, et al. Differential osteiopontin expression in lung cancer. Cancer Lett 2001;171:215-22.
25. Shijubo N, Uede T, Kon S, et al. Vascular endothelial growth factor in stage I lung adenocarcinoma. Am J Respir Crit Care Med 1999;160:1269-73.
26. WHO. The World Health Organization. Histological typing of lung tumours. Am J Clin Pathol 1982;77:123-36.
27. R Development Core Team. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing: 2003.
28. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-26.
29. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. Oxford (UK): Blackwell Publishing: 2002.
30. Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004;10:184-90.
31. Schneider S, Yochim J, Brabender J, et al. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small lung cancer. Clin Cancer Res 2004;10:1588-96.